EU regulators review AZ’ Tagrisso for first-line use in lung cancer
European regulators are reviewing AstraZeneca’s application to market Tagrisso for the first-line treatment of adults with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have EGFR mutations.
Read More
